Cipla spurts on getting EIR from USFDA for facility at Goa

05 Apr 2019 Evaluate

Cipla is currently trading at Rs. 536.00, up by 13.90 points or 2.66% from its previous closing of Rs. 522.10 on the BSE.

The scrip opened at Rs. 528.55 and has touched a high and low of Rs. 537.60 and Rs. 525.25 respectively. So far 2594872 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 678.00 on 19-Sep-2018 and a 52 week low of Rs. 483.75 on 29-Jan-2019.

Last one week high and low of the scrip stood at Rs. 537.60 and Rs. 515.90 respectively. The current market cap of the company is Rs. 42065.66 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 39.60% and 23.69% respectively.

Cipla has received Establishment Inspection Report (EIR) from US Food & Drug Administration (USFDA) for Goa manufacturing facility. The inspection was carried out by USFDA from January 26, 2019 to January 28, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1498.50 -1.50 (-0.10%)
17-Dec-2025 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.45
Dr. Reddys Lab 1273.40
Cipla 1498.50
Zydus Lifesciences 920.00
Lupin 2118.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×